Full Press Release Details
Annual Stockholders Meeting
Inc. Cautionary Statements
presentation contains certain "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, as amended. Such
statements may include statements regarding the efficacy and intended use of
Nephros's technologies under development, the timelines for bringing such
products to market and the availability of funding sources for continued
development of such products and other statements that are not historical facts,
including statements which may be preceded by the words "intends," "may,"
"will," "plans," "expects," "anticipates," "projects," "predicts," "estimates,"
"aims," "believes," "hopes," "potential" or similar words. For such statements,
we claim the protection of the Private Securities Litigation Reform Act of
statements are not guarantees of future performance, are based on certain
assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond the control of Nephros. Actual results
may differ materially from the expectations contained in the forward-looking
statements. Factors that may cause such differences include the risks
that: (i) products that appeared promising in early research or clinical
trials to Nephros may not demonstrate efficacy, safety or cost savings in
subsequent pre-clinical or clinical trials; (ii) Nephros may not obtain
appropriate or necessary governmental approvals; (iii) product orders may be
cancelled, patients currently using Nephros's products may cease to do so and
patients expected to begin using Nephros's products may not; (iv) Nephros may
not be able to obtain funding if and when needed; (v) Nephros's technology and
products, including DSU technology, may not be accepted in current or future
target markets, which could lead to the failure to achieve market penetration
Nephros's products; (vi) HDF therapy may not be accepted in the United States
and/or Nephros's technology and products may not be accepted in target markets;
(vii) Nephros may not be able to sell its products at competitive prices or
profitably; (viii) Nephros may not be able to secure or enforce adequate legal
protection, including patent protection, for its products; and (ix) the
reliability, performance and endurance of Nephros' water filtration device and
technology including its ability to remove a broad range of bacteria, viral
agents and toxic substances, may not be as effective as Nephros believes it
be. More detailed information about Nephros and the risk factors that may affect
the realization of forward-looking statements is set forth in Nephros's filings
with the Securities and Exchange Commission, including Nephros's Annual Report
on Form 10-KSB filed with the SEC for the fiscal year ended December 31, 2005
and its Quarterly Report on Form 10-QSB filed with the SEC for the fiscal
quarter ended March 31, 2006. Investors and security holders are urged to read
those documents free of charge on the SEC's web site at www.sec.gov.
does not undertake to publicly update or revise its forward-looking statements
as a result of new information, future events or otherwise.
technology with key and marketable advantages in both the blood and water
$2.7 million in investment
and license fees; Asahi will develop and market our technology in
Alliance: an important relationship for Nephros
and Development Progress
has happened since year-end?
has happened since year-end?
studies have now shown a 35%+
reduction in mortality for HDF patients vs HD patients
is driving to be the predominant,
provider of HDF therapy in the US beginning in 2007.
has happened since year-end?
difference between unfiltered water and Nephros Filtration in black and
Nephros DSU: A Powerful Performer
Nephros DSU: A Powerful Performer
Shower Flow Rate Nephros DSU vs. Competitive 0.2 Micron
DSU: A Broad Market Opportunity
Strategy: ESRD Therapy
Strategy: Water Filtration
Future of ESRD Therapy